Allergan plc (AGN) and partner Serenity Pharmaceuticals announced that the FDA's Advisory Committee recommended approval for its pipeline candidate SER120 (desmopressin nasal spray) for the treatment of nocturia.
Earnings season kicked off on a positive note for the pharma sector with J&J (JNJ) posting strong results.
Oct 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Allergan, BJ's Restaurants and Lam Research, on Thursday. HIGHLIGHTS * AMC Networks Inc : Pacific Crest cuts to sector weight from overweight * Expedia Inc : Pacific Crest raises to overweight rating * Mid-America Apartment Communities : Jefferies raises to buy from hold * Ventas Inc : Jefferie
Allergan plc (AGN) announced that it has launched Juvederm Voluma XC in the U.S.
Pfizer Inc. (PFE) announced that its Inflectra injection, a biosimilar version of Johnson & Johnson's (JNJ) blockbuster drug Remicade, will be available in the U.S. in late November.
Ireland-based Allergan plc (AGN) has gained worldwide rights to RTGel delivery system technology for use with neurotoxins.
Allergan plc (AGN) announced that its prescription medicine, Belkyra (deoxycholic acid), has been granted marketing approval in Sweden for the treatment of moderate-to-severe fullness under the chin in adults.
Allergan (AGN) supplemental new drug application for antibiotic Avycaz has been accepted for review by the FDA
It's become a well-known fact that investors want to see traction or significant need before they go all-in and bet their money on a new idea. Having previously worked as a financial advisor, I have seen this firsthand: as an investor, you literally have countless new projects and startups to choose from - as well as increased access to data to help you make the most informed choice. So it might not come as a terrible shock to anyone that the world's most renowned venture capitalists are rallying behind life-saving medical products. Yes, biotech has become a hot industry for investors lately, which we've seen detailed in recent business news. Most recently, medical giant, Allergan, recently acquired a very small pharmaceutical company called Tobira for up to one billion dollars based on their new treatments for NASH disease. This story illustrates exactly why biotech companies are so attractive to investors: they tend to stay cost efficient while developing impactful, science-based products, which can be sold for a huge profit. The added bonus for investors is that they can say they are instrumental in saving lives or changing them for the better. One such example is VBI Vaccines INC. (Nasdaq: VBIV), a company that is developing a vaccine for the Zika virus. The Zika virus has been so tricky to contain because it is spread through mosquito bites. Those infected generally get a fever or a rash, but where it really gets dangerous is when pregnant women are involved. These mothers can pass the virus onto their unborn fetus, which can cause debilitating birth defects to the brain or nervous system. Most recent reports detail that 72 countries and territories have reported evidence of mosquito-borne Zika virus transmission since 2007 and 20 countries or territories have reported microcephaly and other CNS malformations potentially associated with Zika virus infection or suggestive of congenital infection. This is why the creation of a vaccine is imperative. VBI has a pipeline of proprietary health technologies, including an eVLP (Enveloped Virus-like Particle), which improves the safety profile and immunogenicity of vaccines by mimicking the natural make-up of viruses. The scientists at VBI are applying the eVLP Platform in the development of a preventative Zika virus ("Zika") vaccine candidate. Their exciting breakthroughs have garnered the support of some of top biotech investors including Joseph Edelman of Perceptive Advisors, Robert Nelsen of Arch Ventures, Dr. Phillip Frost of Opko Health, and Dr. Steven Gillis of Arch Ventures (who serves as VBI's Chairman). This new trend of hyper-focus on biotech is proof that social responsibility is making its mark on business and innovation. Think of all of the great scientific breakthroughs that will be allowed to happen with the proper funding behind them. How many health issues will be solved? How many people will benefit from a higher quality of life? How many lives will be saved? Of course, spending money to make money is obviously an investor's job and yes, biotech companies are certainly profitable (if you don't believe me, check the latest numbers on NASDAQ). But for biotech investors, it's often not all about financial gain - it's about leaving a legacy of better health. And that is truly priceless. -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.
The pharmaceutical industry has had a rough go of it lately. Between negative headlines (with the recent Mylan EpiPen controversy only the latest controversy), congressional inquiries and calls from insurers and the medical community to defend the price of medications, today's value-focused healthcare landscape presents an unprecedented set of challenges for the sector. This new level of pressure is exemplified by legislation currently under consideration in more than 10 states - including California, New York and Massachusetts - that would require drug manufacturers to disclose (and ultimately justify) costs of R&D, production and marketing. This degree of regulated transparency would be unheard of in most industries. But it underscores the need for pharmaceutical companies to adjust their approach and refocus on their core stakeholders in today's quickly evolving and increasingly tightening healthcare ecosystem. There are three core tenets pharma companies should keep in mind to ensure buy-in and trust from payers, physicians and patients - and of course investors - as we all adapt to the current environment: The story needs to start with the patient - being able to understand and quantify how new products coming to market will make a real difference for patients is essential to demonstrating value in a value-based system. For example, Johnson & Johnson has always been a leader in patient-focused initiatives, and companies such as Allergan are emerging as well, with the company's Growth Pharma model. Allergan has cited customer intimacy as a key focus, including a deep understanding of therapeutic area environments and a commitment to being responsive and service-oriented. Similarly, as my company OptiNose worked to develop our product to treat chronic rhinosinusitis, we sought to root every decision we made against the backdrop of the patient disease. We engaged with patients and physicians through a study to understand the level of unmet need and to identify the product benefits vital to delivering a better outcome. We found that chronic rhinosinusitis was afflicting nearly 28 million people a year in the U.S., (with nearly 18 million suffering severely most of the year), and that less than 25 percent of the physician specialists were happy with the current treatment options. Outcomes aren't a dirty word - according to a recent survey of 42 U.S. health plans, they are increasingly focused on being able to pay for medications based how much the drug measurably helps the patient. While the chief attention right now is on high-cost specialty drugs, the survey found that for some conditions as high as 63 percent of the insurers had "strong interest" in establishing outcomes-based contracts. Agreeing on key components like metrics, data collection and patient follow-up will all be a challenge. But it's also an opportunity. Several of the big drug companies have signed some form of these type of deals, including Novartis's value-based price agreement with Cigna and Aetna for heart-failure drug Entresto. The lesson here is that while this type of change is never easy, it's essential companies keep an open mind and acknowledge that a solutions-focused mentality will ultimately provide better outcomes to patients and all stakeholders. Innovation is still key (even if it's done differently) - a major challenge for the industry has been overcoming the criticism that as we move away from traditional R&D, incremental innovation becomes the mark. "Me too" drugs and price hikes for branded drugs have become easy targets - understandably. What's key to remember is that innovation can occur in different ways. It's about communicating the benefits of other types of innovation and thinking outside the box. We realized that by starting with carefully selected molecules that were already approved, OptiNose could develop new products based on our delivery technology that could significantly improve the current standard of care for patients (and significantly minimize drug development costs). As long as you articulate how you are delivering value and what the end benefit is for patients, stakeholders' appreciation for non-traditional innovation in the sector should continue to evolve. Driven by pressures brought to bear on every player, our healthcare system has become quite dynamic in recent years. At times of especially rapid and significant change like this, it's vital the pharma industry focus on its core stakeholders and remain open to new approaches. Our industry has proven its capability to deliver significant value to patients--which is part of what makes the being an executive in the sector uniquely rewarding. I am confident that my peers will do what is necessary to adapt and grow in this new healthcare environment. -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.
Generic drug maker, Teva Pharmaceutical Industries Ltd. (TEVA) has entered into an exclusive biosimilar commercial partnership with Celltrion, Inc and its distribution partner Celltrion Healthcare.
Repros Therapeutics' (RPRX) regulatory application for enclomiphene has been accepted for review in the EU.
Очередной flash crash "накрыл" рынки Вчерашние торги оказались банальными донЕльзя! Конечно, многие еще до начала торгов предполагали, что ничего интересного не будет и изменения будут минимальными. Рынок должен был взять паузу. И он действительно ее взял. Причем фактически все торги завершились через 2 часа после их старта и большую половину дня индексы просто стояли и никуда не двигались. В итоге, максимальное изменение наблюдалось в индексе NASDAQ, который потерял АЖ!!! -0,17%. Произошло это в основном за счет небольшой распродажи акций медицинских и биотехнологических компаний. Этот сектор пострадал вчера более всего и потери составили в среднем 0,7%. Из этого сектора только акции Allergan (AGN) показали положительную динамику и выросли на 0,72%. Со вчерашнего дня эти акции начали торговаться и на Санкт-Петербургской бирже.
Все же общий настрой рынков сегодня после случившегося «флэш-крэша» умеренно негативный. Даже скажем точнее - настороженный.
Teva Pharmaceutical Industries Ltd. (TEVA) announced that it has agreed to divest the U.K. and Ireland assets of Actavis Generics to Accord Healthcare, a subsidiary of Intas Pharmaceuticals Ltd.
Once again, acquisitions and deals were in focus in the pharma sector -- Lilly (LLY) signed a deal to boost its animal health segment and others announced licensing deals.